L-asparaginase therapy and its complications in acute lymphoid leukaemia and generalized lymphosarcoma.
D000293:Adolescent; D000707:Anaphylaxis / Q000209:etiology; D001215:Asparaginase / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003221:Confusion / Q000139:chemically induced; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced; D011239:Prednisolone / Q000627:therapeutic use; D012187:Retroperitoneal Space; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D014747:Vinblastine; D011239:Prednisolone; D015122:Mercaptopurine; D001215:Asparaginase; D008727:Methotrexate; D003630:Daunorubicin